This peptide is H2-Kd-restricted enhanced green fluorescent protein (EGFP)-derived peptide (200-208) and represents a CD8 T cell epitope. Immunization with this peptide stimulates IFNg production, thus making this peptide a model tumor antigen for the experimental development of antigen-specific vaccines against cancer.
Usually ships within 24 hours.